Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol in younger patients with essential hypertension
NCT01415531Phase 4Completed
- Sponsor
- Forest Laboratories
- Start
- Aug 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in essential hypertension comparing Nebivolol with Placebo (2 arms). Primary endpoint: Trough Seated Diastolic Blood Pressure at 8 weeks. Started Aug 2011; status: completed.
02
Drugs
nebivolol
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01415531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01415531.